News | February 03, 2009

Medtronic Completes Study Enrollment to Compare Stent Safety

February 3, 2009 – Medtronic has completed enrollment in PROTECT, the company’s global study comparing its Endeavor drug-eluting stent (DES) to Johnson & Johnson’s Cypher DES.

Said to be the first and largest randomized controlled trial (RCT) of its kind, PROTECT is powered to detect a clinically significant difference in rates of stent thrombosis between the two devices. Stent thrombosis is a rare but serious adverse event in which a blood clot forms inside the stent, with the potential to cause heart attack or death. Occurrences after one year post-implant are called very late stent thrombosis (VLST) and a subject of significant concern.

“The scale and scope of this trial will make the results applicable to a wide spectrum of practices worldwide. PROTECT will yield contemporary data on stent thrombosis rates and other clinically relevant endpoints for these two drug-eluting stents, including the role of antiplatelet therapy after their implantation. Thanks to the efforts of our fellow investigators and their teams, PROTECT successfully randomized 8,800 patients in 18 months,” said William Wijns, M.D., of the Cardiovascular Center in Aalst, Belgium; Prof. Philippe Gabriel Steg of Hôpital Bichat-Claude Bernard in Paris, France; and Edoardo Camenzind, M.D., of University Hospital Geneva in Switzerland, the investigators representing the trial’s steering committee.

“With the Endeavor DES, the rate of VLST appears to be remarkably and sustainably low – a reassuring record,” said steering committee member William O’Neill, M.D., of the University of Miami School of Medicine in Florida. “While the Endeavor DES has demonstrated durable efficacy to four years of patient follow-up in comparison to other DES, its long-term safety profile resembles that of a bare-metal stent (BMS), the benchmark for stent safety. PROTECT puts this contention to the test in a large RCT.”

The trials that supported the regulatory approvals of the Endeavor DES have shown no increase in the rate of VLST compared with its BMS control and no new events after two years through four years of follow-up. These observations served as the rationale for PROTECT.

PROTECT’s primary endpoint is overall stent thrombosis at three years; secondary endpoints include death and non-fatal myocardial infarction (MI), target lesion revascularization (TLR) and target vessel revascularization (TVR). Three-year data are expected to be available in 2012.

For more information: www.medtronic.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init